The Pharma Letter Pharmaletter News Articles
Brexit hardly the medicine for a Europe craving innovation
Anyone unfamiliar with pharma might be puzzled by how often the word ‘innovation’ comes up in dialogue,…
Early data from Phase III Northstar-2 study of LentiGlobin
US clinical-stage biotech firm bluebird bio’s shares closed down 5.5% at $112.00, having fallen as…
Astellas suspension from UK trade group extended for further year
Astellas Pharma’s suspension as a member of the Association of the British Pharmaceutical Industry…
Japanese plant padded paracetamol with cheap Chinese imports
Active ingredients supplier Yamamoto Chemical Industry has been blocked from shipping its products after…
No harm to brain function from Zebinix/Aptiom, data shows
Portuguese pharma firm BIAL and Japan’s Eisai have announced data from a Phase II study which showed…
Proposed ACA replacement intensifies US health debate
Republicans have taken the chance to aim further criticism at the Affordable Care Act (ACA) amid US Senate…
Five new meds, one biosimilar and two generics recommended for approval by EMA’s CHMP
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five…
Novartis gains US approval for combination therapy in NSCLC
The US Food and Drug Administration has granted drugmaker Novartis approval to market Tafinlar and Mekinist…
Latest on clinical benefit of tramiprosate in Alzheimer’s
Positive results published today by closely-held US biotech firm Alzheon, in The Journal of the Prevention…
CSL Behring wins approval for first subcutaneous HAE therapy
Haegarda, a therapy for hereditary angioedema (HAE) from biotech firm CSL Behring, has been approved…
Lundbeck shares slip after FDA rebuff
Shares in Danish CNS specialist Lundbeck have fallen 4% on the news that the company, together with development…
LEO Pharma appoints Chris Posner to lead US business
Danish drugmaker LEO Pharma today announced that it appointed Chris Posner as executive vice president…
FDA approves Rituxan Hycela in multiple blood indications
The US Food and Drug Administration yesterday approved Rituxan Hycela, the combination of Genentech’s…
Ewopharma to commercialize Eisai drugs in Central Eastern Europe
Ewopharma revealed yesterday that, as of April 1 this year, it has acquired the rights to commercialize…
Indivior presents Phase III data on sustained-release opioid addiction therapy
UK-based Indivior has presented Phase III results from a trial into RBP-6000, an investigational once-monthly…
Mylan shareholders reject executive pay plan
Shareholders of beleaguered Netherlands-incorporated drugmaker Mylan voted against the company's executive…
Fertility specialist delivers new head, months overdue
US fertility treatment specialist OvaScience will cut its workforce and appoint a new chief executive,…
Novartis jumps on surprise success of CANTOS study
With its shares up 5% at 83.85 Swiss francs by late afternoon, Novartis led gainers on the SIX Exchange,…
Positive decision for Santhera sends share price soaring
The UK's medicines regulator has given a positive scientific opinion to Santhera Pharmaceuticals’ …
Brazil one of the most attractive pharmaceutical markets, new research indicates
Brazil is one of the most attractive and promising pharmaceutical markets in the world, with all major…
Draft Trump order abandons campaign promises to challenge Big Pharma, says consumer advocacy group
The New York Times published an analysis of a draft Trump executive order on prescription pricing and…
EMA to review Shire application for blood disorder therapy
The European Medicines Agency has agreed to review London-listed Shire's application for approval to…
As Anthem withdraws, tremor in foundations of Obamacare
Anthem is pulling out of health insurance exchanges in Wisconsin and Indiana, a decision cheered by Republicans…
Verona Pharma names former Sanofi exec as VP regulatory affairs
UK clinical-stage biopharma firm Verona Pharma today announced the appointment of Desiree Luthman to…
The rise of AMR and the threat to medical progress
In an Expert View piece, Karl Rotthier, chief executive of sustainable antibiotics company DSM Sinochem…
Group starts buying assets to become ‘pan-European leader’ in CNS diseases
The Invent Farma/neuraxpharm, a group created by funds advised by private equity firm Apax Partners in…
Rubius Therapeutics bolsters its cell therapies mission by $120 million
A US biotech which calls itself the pioneer of a ‘new class of extraordinarily active and differentiated…
Middlemen jittery as Amazon's creepers move toward pharmaceuticals
One interesting corollary of Amazon’s recent acquisition of Whole Foods was the effect on pharmacies,…
SerImmune enters collaboration with Merck
California, USA-based SerImmune has entered into a research and development collaboration agreement with…
Drug majors join BIO Ventures to tackle cancer crisis in Africa
BIO Ventures for Global Health (BVGH), is launching the African Access Initiative (AAI) today at the…
Feed Fetched by RSS Dog.